Disease overview (Classification of Acromegaly)
 Approved and Emerging therapies (Pipeline assessment and key clinical trials profile)
 Epidemiology (Incidence, prevalence, mortality and survival)
 Market share and patient share uptake
 KOL’s perspective on current treatment & unmet needs
 Market and product event analysis
 Market forecast 2020 - 2030 (11 years of future market projections)

Report Summary

Thelansis “Acromegaly - Market outlook, Epidemiology, Market Forecast and Competitive Land- scape - 2020 To 2030 ” this report provides a comprehensive study of the disease area land- scape and changing market dynamics with respect to the cur- rent & future market events for the 8 MM countries (USA, EU5, Japan & China).

Report Overview

The report provides a comprehensive view of disease events, classification, identified and emerging, Clinical Manifestations, progression, signs & symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines at country level

View Report: https://thelansis.com/reports/acromegaly-market-outlook-report/

Acromegaly Market Comprehensive insight on patient segmentation based on Origin (Pituitary Tumor & Non-Pituitary Tumor), Adenoma size (Macroadenomas and Microadenomas), responsive to treatment (Surgical & Non-surgical), Clinical Manifestations (osteoarticular manifestation, cardiovascular manifestation, respiratory manifestation, gastrointestinal manifestation, endocrinological and other manifestations) has been provided into the epidemiology (Incidence and Prevalence) section of the Acromegaly and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.

Drug utilization and analysis on the current clinical practice, KOL perspective on upcoming therapies, estimated TPP for pipeline as- sets, clinical characteristics upcoming therapies and future treatment paradigm.
Market aggregation on newly diagnosed patient pool, Thelansis estimation on persistence, compliance, adherence and a historic view of changing market dynamics and product-level patient flow of Acromegaly in the 8 MM Countries for the period 2020 – 2030. 

Epidemiology

Disease Overview

Acromegaly is a hormonal disorder that results from the availability of too much growth hormone (GH) in the body. The pituitary, a small gland in the brain, makes GH. In acromegaly, the pituitary produces excessive amounts of GH. Usually, the excess GH comes from benign, or noncancerous, tumors on the pituitary. These benign tumors are called Adenomas.

Competitive Landscape

Acromegaly Market Scenario:

There are three dimension treatment pattern are being under practice such as; surgery, medical therapy and radiotherapy. Pituitary surgery is recommended as the primary treatment in patients with microadenomas and in patients with macroadenomas that are associated with local mass effects or are enclosed and potentially curable surgically because surgery can lead to durable control of the tumor mass and associated biochemical effects.

Acromegaly Market Forecast

Thelansis’ research team expects the Acromegaly market potential for 2030 at $X.XXB in 8MM countries. Out of this market, 52.5% sales are expected to be contributed from the US market whereas XX.X% is expected to come from EU-5. Japan and China are expected to contribute XX.X% and X.X% respectively.

Acromegaly Products Pricing Scenario:

Upcoming therapy probably transform the treatment paradigm of Acromegaly in the near future. Clinical trials some level of promising results like proportion of patients maintaining their baseline and in most of the patients, without causing significant safety concerns. Of course, some questions about targeted therapy still remain un- solved.

Based on the KOL Insights gathered from Primary Market Research (PMR) of Acromegaly market Thelansis expects upcoming therapies may raise significant concerns with respect to the treatment cost as much as USD 85,000 to USD 124,000 per patient. To control the cost research have developed algorithm for tiered testing guide to enhance the clinical diagnosis of Acromegaly, in the other hand it is hard to distinguish genetic variations such as pin- pointing the phenotype and exact biomarker.

Contact Us

About Thelansis: - As the name depicts Thelansis is specialized in “Therapy Area Landscape Analy- sis” along with market intelligence and consultancy that supports pharmaceutical, biotechnology, and diagnostics companies to successfully prepare, launch, and commercialize their products. Our Syndicated research reports include Market Insight, Pipeline Insight, Product Insight, Specialized Reports, Indication Outlook and Market Access Reports. Our focused therapeutic approach provides our clients with clinical and disease area expertise from an integrated team of academic, medical, and industry specialists of our panel, Ask for our report offerings, and Indication specific sample pages by sharing your email ID with us at,

[email protected]

Peeyush Potdar

Delivery Head:

Email: [email protected]

Visit us at http://www.thelansis.com/

Delivery office
B-1030, C Wing
Vrindavan tech village Marathahalli
Outer ring road, Bangalore- 560037

Sales office
183-Asylum Street Hartfort, CT-06103, USA

Telephone
USA +1-302-380-3552 India +91-9899921259

Email
[email protected] [email protected]